Priority I Reference Table

Question 1How can randomised trials become part of routine care and best utilise current clinical care pathways?
Question 2What information should trialists communicate to members of the public who are being invited to take part in a randomised trial in order to improve recruitment to the trial?
Question 3Does patient/public involvement in planning a randomised trial improve recruitment?
Question 4What are the best approaches for designing and delivering information to members of the public who are invited to take part in a randomised trial?
Question 5What are the barriers and enablers for clinicians/healthcare professionals in helping conduct randomised trials?
Question 6What are the key motivators influencing members of the public’s decisions to take part in a randomised trial?
Question 7What are the best approaches to ensure inclusion and participation of under-represented or vulnerable groups in randomised trials?
Question 8What are the best ways to predict recruitment rates to a randomised trial and what impact do such predictions have on recruitment?
Question 9What are the best approaches to optimise the informed consent process to improve recruitment of members of the public to randomised trials?
Question 10What are the advantages and disadvantages to using technology during the recruitment process?
Question 11How best can clinicians and other health professionals be educated to optimise recruitment to randomised trials?
Question 12Does feasibility testing of recruitment procedures lead to improvements in recruitment?
Question 13How can eligibility criteria for trial participants be optimised so that they aid recruitment to randomised trials?
Question 14What is the value of making trials participants feel appreciated in being recruited to a trial and how can this be best achieved?
Question 15What are the best approaches to ensuring manageable workloads for clinical and research staff responsible for recruiting members of the public to randomised trials?
Question 16Does involvement of (i) members of the public and/or (ii) members of the public participating in a randomised trial, in designing trial information improve recruitment?
Question 17What are the incentives that motivate members of the public to agree to participate in randomised trials?
Question 18Do trial recruiters who have received focused, specialised recruitment training achieve better levels of recruitment than non-trained recruiters?
Question 19Do randomised trials which have a low participant burden/requirements achieve better recruitment than those that have a greater patient burden?
Question 20Does a central registry for members of the public (i.e. a list of people with contact details) who are interested in taking part in a randomised trial improve recruitment?

Priority II Reference Table

Question 1What motivates a participant’s decision to complete a clinical trial?
Question 2How can trials make better use of routine clinical care and/or existing data collection to improve retention?
Question 3How can trials be designed to minimise burden on staff and participants and how does this affect retention?
Question 4What are the best ways to encourage trial participants to complete the tasks (e.g. attend follow-up visits, complete questionnaires) required by the trial?
Question 5How does involvement of patients/the public in planning and running trials improve retention?
Question 6How could technology be best used in trial follow-up processes?
Question 7What are the most effective ways of collecting information from participants during a trial to improve retention?
Question 8How does a participant’s ongoing experience of the trial affect retention?
Question 9What information should trial teams communicate to potential trial participants to improve trial retention?
Question 10How should people who run trials plan for retention during their funding application and creation of the trial (protocol development)?
Question 11What aspects of trial recruitment processes could be changed to improve retention?
Question 12What aspects of trial retention do participants perceive as burdensome and how can these be addressed?
Question 13What influence does the relationship between trial staff and participants have on retention?
Question 14How does a sense of belonging or being part of something amongst trial participants affect retention?
Question 15What are the best approaches for designing and communicating information about trial retention for trial participants?
Question 16To what extent (if any) do studies that explore retention procedures before the main trial (i.e. feasibility study) lead to improvements in retention in the main trial?
Question 17What is the impact of timing, frequency and duration of follow up (e.g. questionnaires, clinic appointments) on retention?
Question 18What strategies (e.g. sending Christmas cards or saying ‘thank you’) make participants feel valued and how do they affect retention?
Question 19What are the best strategies for using participant incentives (e.g. monetary or non-monetary) and how should they be implemented (e.g. when should they be provided) when collecting information from participants in clinical trials?
Question 20How does continuity (e.g. seeing/speaking to the same staff) and consistency (e.g. of trial information) affect retention?
Question 21What behaviours of trial staff (e.g. being friendly) result in improved retention?